Close Menu

NEW YORK – Exact Sciences announced today that it has entered into a deal to acquire Genomic Health for $2.8 billion in cash and stock.

In a separate announcement, the company reported its second quarter earnings rose 94 percent year over year, due to a 93 percent increase in testing volumes from its Cologuard colorectal cancer diagnostic.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.